stockrowZymeworks Inc.
ZYME Healthcare Biotechnology
Zymeworks Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.0 million, up 38.9% from fiscal 2024.
- Revenue
- −90.6%
- EPS
- −2,166.7%
- Free cash flow
- −385.5%
Quarter to June 2026, against a year earlier
Follow ZYME
Alert me
Zymeworks Inc. (ZYME) Return on assets
Zymeworks Inc.'s return on assets over the twelve months to 30 June 2026 was −37.3%, down 17.2 percentage points from fiscal 2025 (−20.0%). Over the past ten years it has ranged from −57.7% (fiscal 2016) to 24.0% (fiscal 2022); the current reading is higher than 64% of that period. That is above the Biotechnology industry median of −45.6% and below the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −20.0% | 3.47 |
| FY2024 | −23.5% | (4.21) |
| FY2023 | −19.3% | (43.26) |
| FY2022 | 24.0% | 69.64 |
| FY2021 | −45.7% | (5.85) |
| FY2020 | −39.8% | 7.65 |
| FY2019 | −47.5% | (28.06) |
| FY2018 | −19.4% | (9.75) |
| FY2017 | −9.67% | 48.05 |
| FY2016 | −57.7% | (24.99) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | 46.5% |
| VCEL Vericel Corporation compare | 6.86% |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 0.00% |
| SEPN Septerna, Inc. compare | −4.94% |
| COAG Hemab Therapeutics Holdings, Inc. compare | −31.8% |
| ZYME Zymeworks Inc. | −37.3% |
| IMNM Immunome, Inc. compare | −59.0% |
| VERA Vera Therapeutics, Inc. compare | −72.3% |
| BHVN Biohaven Ltd. compare | −161.3% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on ZYME
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement